Axovant IPO sparks talk of a biotech bubble
June 12, 2015 at 14:38 PM EDT
Axovant has just one drug candidate, a 29-year old CEO — and a market cap of nearly $3 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.